Therapeutic drug monitoring of posaconazole for effective prophylaxis of invasive fungal infections in pediatric patients: a pilot study

Karolina Liszka#*1, Matylda Resztak#2, Paulina Zalewska2, Krzysztof Kałwak1

1Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wrocław Medical University, Wrocław, Poland
2MonitLab Sp. z o.o., Poznan, Poland

*Authors contributed equally to work

Abstract
Introduction: Posaconazole, a second-generation triazole agent, is a drug with wide interindividual variation in bioavailability and variability of pharmacokinetics. The European Conference on Infections in Leukemia recommends the implementation of posaconazole therapeutic drug monitoring (TDM) in children to provide certainty regarding the efficacy of treatment and to increase its safety. A concentration of posaconazole in plasma in prophylactic regimens of above 0.7 mg/L is recommended.

The aim of our pilot study was to discover the most effective method of posaconazole plasma concentration measurement, and to analyze posaconazole pharmacokinetics profiles in pediatric patients on posaconazole prophylaxis.

Material and methods: Children receiving oncological treatment or hematopoietic stem cell transplantation in the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology in Wrocław Medical University Hospital were included in the trial. Posaconazole concentration was determined at the MonitLab™ laboratory using a newly validated high-performance liquid chromatography with fluorescence detector method.

Results: Initial analysis shows that the major problem in patients on antifungal prophylaxis is inadequately low plasma drug concentration.

Conclusions: Clinical trials on TDM of posaconazole should be developed.

Key words: posaconazole, therapeutic drug monitoring (TDM), antifungal prophylaxis

Introduction

The appropriate medication dosage often depends on a patient’s individual metabolism patterns, and therefore closer cooperation between physicians and pharmacologists seems sensible. One solution that enables therapy to be customized to the individual patient’s needs is therapeutic drug monitoring (TDM).

TDM provides certainty as to the efficacy of treatment by confirming that the plasma concentration of medicine is fixed within the desired level. It increases the safety and efficacy of the implementation of the drugs within a narrow therapeutic range (NTR).

Posaconazole is a second-generation triazole agent with a broad spectrum of activity against a range of important fungal pathogens including: Aspergillus spp.,...
Candida spp., Mucormycetes spp., and Fusarium spp. As a result, it is widely used in pediatric onco-hematological wards, because fungal infections are one of the most frequent complications that occur in immunocompromised patients. Appropriate prophylaxis and targeted treatment decrease mortality rates significantly. However, it should be remembered that the therapeutic efficacy of posaconazole is conditional upon achieving a plasma drug concentration target at a steady state, which should be considered as an equivalent to the minimum inhibitory concentration (MIC$_{90}$) for a pathogen causing an infection.

Posaconazole is a drug with wide interindividual variation in bioavailability and well-recognized variability of pharmacokinetics. For that reason, the European Conference on Infections in Leukemia (ECIL) recommends the implementation of posaconazole TDM in children as routine practice to ensure an adequate exposure, and to optimize the clinical response [1].

Medicines involved in drug-to-drug interactions (DDIs) can be divided into two groups: victims — i.e. drugs that are directly affected by DDIs, and perpetrators — i.e. drugs that cause DDIs. Posaconazole can act in both ways. It can be affected as a victim drug by interactions with medicines that interact with uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes or P-glycoprotein. Nearly 20% of posaconazole is glucuronidated by UGT1A4. Both inducers (e.g. rifampicin, some anticonvulsants) and inhibitors of the enzyme (e.g. verapamil, cyclosporin A, macrolides) can alter posaconazole’s plasma concentration.

On the other hand, posaconazole is also an inhibitor of CYP3A4, so it affects the metabolism of drugs that are substrates for that enzyme, such as cyclosporin A [2].

Although posaconazole is characterized by better tolerance and fewer interactions than other azoles, its pharmacokinetics is affected also by other factors such as: the clinical condition of the patient, the patient’s age, the route of drug administration, and the means of the patient’s feeding, all of which can be associated with altered medicine absorption. It is recommended to ingest this medication with a meal that is rich in lipids, or with soda drinks that increase the acidity. Proton pump inhibitors, as well as metoclopramide or gastrointestinal tract disorders such as mucositis or diarrhea, are known to decrease the bioavailability of posaconazole [2]. Because of this, these patients require especially precise dose adjustments according to posaconazole’s plasma concentration in order to provide effective antifungal treatment or prophylaxis.

In Poland, two posaconazole formulations are available: ■ suspension (this has possible bioavailability issues, is reimbursed for antifungal prophylaxis in patients who underwent hematopoietic stem cell transplantation (HSCT) and who receive high dose immunosuppressive drugs due to graft-versus-host disease (GvHD) — children with myelodysplastic syndrome (MDS) prepared for HSCT, secondary antifungal prophylaxis after HSCT, chronic granulomatous disease with frequent fungal organ infections, children with acute myeloblastic leukemia (AML), myelodysplastic syndrome, acute lymphoblastic leukemia (ALL), recurrence of ALL or AML, malignant lymphomas or solid tumors receiving chemotherapy that can lead to prolonged neutropenia with high risk of fungal infections, and secondary antifungal prophylaxis until chemotherapy or immunosuppressive therapy is completed; ■ intravenous formulation (this is expensive, and is used in rare cases of patients who are unable to take the suspension).

Until now, slow-release tablets have not been available in Poland, although they offer much better bioavailability and stability [2].

According to ECIL-8 recommendations, the suggested concentration of posaconazole in plasma in prophylactic regimens is a concentration of above 0.7 mg/L [1]. It has been demonstrated that a concentration above 3 mg/L can be associated with the occurrence of side effects. If we derive our data from voriconazole, then a concentration of above 6 mg/L would be considered as associated with toxicity (predominantly neurotoxicity) [3].

TDM in clinical practice is based on measuring plasma drug concentration at designated intervals, when the steady state in patients’ blood is obtained. For posaconazole, this is reached after 7–10 days of therapy. The main purpose of the implementation of posaconazole TDM in everyday practice is to improve the safety of posaconazole therapy in a way that will enable us to achieve the optimal medical outcome and limit side effects. To implement TDM of posaconazole in standard routine practice, we need a method of serum concentration assessment that is simple, quick, and cost effective.

The aim of our pilot study was to find the most effective method of posaconazole pharmacokinetics (PK) measurement, and to analyze PK profiles in pediatric patients on posaconazole prophylaxis.

**Material and methods**

Our subjects were selected from patients treated in the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology at Wroclaw Medical University, Wroclaw, Poland. The protocol for this study was approved by the Wroclaw Medical University Ethics Committee before the study began. All the patients were administered posaconazole according to the Welzen’s et al. [4] dosing recommendations. In the first phase of our clinical trial, we assessed a group of patients on posaconazole prophylaxis. We measured plasma drug concentration and we tried to review the impact of additional factors on posaconazole pharmacokinetics, factors that when compared to clinical data could help us to reach conclusions as to adequate and safe dosage modification in the future.
### Table I. Clinical trial results

<table>
<thead>
<tr>
<th>No.</th>
<th>Diagnosis</th>
<th>Age in years</th>
<th>Weight in kg</th>
<th>Treatment stage</th>
<th>Day on POSA</th>
<th>C 0H</th>
<th>C 3H</th>
<th>C 5H</th>
<th>C 8H</th>
<th>Median Con.</th>
<th>Drugs with possible interaction with POSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CD40 ligand def.</td>
<td>2</td>
<td>11</td>
<td>Day +14 after allo-HSCT</td>
<td>25</td>
<td>0.74</td>
<td>1.02</td>
<td>1.05</td>
<td>1.21</td>
<td>1.04</td>
<td>Acyclovir, colistin, meropenem, teicoplanin, cyclosporin</td>
</tr>
<tr>
<td>2</td>
<td>ALL</td>
<td>4</td>
<td>14.6</td>
<td>Day +49 after allo-HSCT</td>
<td>60</td>
<td>0.87</td>
<td>1.18</td>
<td>0.92</td>
<td>0.63</td>
<td>0.90</td>
<td>Sulfamethoxazole/trimethoprim, ursodeoxycholic acid</td>
</tr>
<tr>
<td>3</td>
<td>ALL</td>
<td>7</td>
<td>30.5</td>
<td>Day 6 HC1 IntReALL 2010</td>
<td>10</td>
<td>0.67</td>
<td>0.72</td>
<td>0.66</td>
<td>0.56</td>
<td>0.67</td>
<td>Acyclovir, meropenem, cyclosporin, ursodeoxycholic acid</td>
</tr>
<tr>
<td>4</td>
<td>AML</td>
<td>3</td>
<td>11.5</td>
<td>Day –8 before allo-HSCT</td>
<td>90</td>
<td>0.44</td>
<td>0.63</td>
<td>0.56</td>
<td>0.50</td>
<td>0.53</td>
<td>Sulfamethoxazole/trimethoprim, acyclovir, ciprofloxacin, omeprazole</td>
</tr>
<tr>
<td>5</td>
<td>ALL</td>
<td>10</td>
<td>30</td>
<td>Year after allo-HSCT, GvHD</td>
<td>90</td>
<td>2.46</td>
<td>2.77</td>
<td>2.71</td>
<td>2.39</td>
<td>2.59</td>
<td>Acyclovir, omeprazole, methyprednisolone, cyclosporin, acyclovir, ursodeoxycholic acid</td>
</tr>
<tr>
<td>6</td>
<td>ALL</td>
<td>16</td>
<td>61</td>
<td>Day +33 after allo-HSCT, GvHD</td>
<td>8</td>
<td>0.26</td>
<td>0.32</td>
<td>0.30</td>
<td>0.33</td>
<td>0.31</td>
<td>Sulfamethoxazole/trimethoprim, acyclovir, ursodeoxycholic acid</td>
</tr>
<tr>
<td>7</td>
<td>Lymphoma</td>
<td>16</td>
<td>55.5</td>
<td>Day +27 after allo-HSCT</td>
<td>8</td>
<td>1.42</td>
<td>1.02</td>
<td>1.56</td>
<td>1.23</td>
<td>1.33</td>
<td>Acyclovir, rifaximin, ursodeoxycholic acid</td>
</tr>
<tr>
<td>8</td>
<td>WAS</td>
<td>5</td>
<td>18</td>
<td>Day +50 after allo-HSCT, GvHD</td>
<td>18</td>
<td>0.96</td>
<td>1.06</td>
<td>1.02</td>
<td>0.77</td>
<td>0.99</td>
<td>Amlodipine, atenolol, mycophenolate mofetil, colistin, cyclosporin, etanercept, foscarnet sodium, methyprednisolone, leternovir, rifaximin</td>
</tr>
<tr>
<td>9</td>
<td>Lymphoma</td>
<td>16</td>
<td>59</td>
<td>Day +3 after allo-HSCT</td>
<td>15</td>
<td>0.37</td>
<td>0.45</td>
<td>0.39</td>
<td>0.27</td>
<td>0.38</td>
<td>Sulfamethoxazole/trimethoprim, hydrocortisone, colistin, acyclovir, ursodeoxycholic acid, cyclosporin</td>
</tr>
<tr>
<td>10</td>
<td>ALL</td>
<td>11</td>
<td>33</td>
<td>Day +10 after CAR-T 17 days after Protocol II AIEOP-BFM ALL 2017</td>
<td>400</td>
<td>0.69</td>
<td>0.86</td>
<td>0.84</td>
<td>0.76</td>
<td>0.80</td>
<td>Sulfamethoxazole/trimethoprim, ciprofloxacin, acyclovir, levetiracetam, tocilizumab</td>
</tr>
<tr>
<td>11</td>
<td>ALL</td>
<td>6</td>
<td>30</td>
<td>Day +18 after HSCT</td>
<td>7</td>
<td>3.06</td>
<td>3.65</td>
<td>2.93</td>
<td>2.75</td>
<td>3.00</td>
<td>Sulfamethoxazole/trimethoprim, nystatin</td>
</tr>
<tr>
<td>12</td>
<td>AML</td>
<td>4</td>
<td>18</td>
<td>Day +18 after allo-HSCT</td>
<td>28</td>
<td>0.7</td>
<td>0.62</td>
<td>0.63</td>
<td>0.55</td>
<td>0.63</td>
<td>Sulfamethoxazole/trimethoprim, ciprofloxacin, acyclovir, cefpime, cyclosporin, teicoplanin, ursodeoxycholic acid</td>
</tr>
</tbody>
</table>
Blood samples were obtained from 15 patients during their hospitalization. The samples were taken after seven days of treatment with posaconazole, after reaching the drug steady state at four time points: 0 — just before the drug administration, and then three, five and eight hours after. The sample volume needed for analysis was 0.5 mL. All blood samples were centrifuged (3,500 g at 20°C for 5 min) and plasma was stored at –20°C until analysis. For drug administration, and then three, five and eight hours after. The sample volume needed for analysis was 0.5 mL. All blood samples were centrifuged (3,500 g at 20°C for 5 min) and plasma was stored at –20°C until analysis. For each plasma sample, posaconazole concentration was determined at the MonitLab™ laboratory in Poznan, Poland using a newly validated high-performance liquid chromatography with fluorescence detector (HPLC-FLD) method. Chromatographic separation was achieved with the mobile phase consisting of acetonitrile/water with a flow rate of 1.3 mL/min. Each sample injection volume was 2 μL. 50 μL of patient plasma was used for the analysis. Protein precipitation procedure was applied for the extraction of posaconazole from plasma samples. The validation of the analytical method was carried out according to the guidelines on bioanalytical method validation of the European Medicines Agency (EMA).

Results

Demographics and TDM
The ages of our preliminary group of patients ranged from one to 16 years. 10 out of 15 patients included in the trial were diagnosed with leukemia, two patients suffered from lymphoma, and three had immunodeficiency syndromes such as CD40 ligand deficiency and Wiskott-Aldrich syndrome (WAS). 6/15 patients (40%) included in the trial presented with the desired plasma concentration of posaconazole in the intervals between doses. In 7/15 patients (47%), the plasma concentrations of posaconazole were lower, and were considered to be insufficient. All of these patients remained in the HSCT procedure, either before (n =2) or after HSCT (n =5). Two out of three patients who received parallel omeprazole had low posaconazole plasma concentrations.

In two patients (13%), plasma posaconazole concentration reached an alarming level, bordering toxicity. Both these patients showed no known toxicity symptoms. Both were patients with ALL. The first patient was after the II protocol and the second one was during the lb protocol (AiEOP-BFM ALL 2017) (Table I). This led us to hypothesize that the reason for the elevated plasma concentration of posaconazole was related to metabolic drug interaction.

Interactions and side effects
Our initial study results revealed that insufficient plasma drug concentration is the major problem in patients on antifungal prophylaxis. Inadequately low concentrations appear more frequently than do toxic levels. We cannot assess the correlation between the length of prophylaxis implementation in a patient and the low serum concentration of posaconazole so far. The problem affects both children on long-term treatment as well as patients who have just started oral antifungal prophylaxis. On the other hand, alarmingly high plasma serum concentrations of the drug occurred among patients who had just started their prophylactic regimen – both of the patients were tested on day 7 following the start of their oral posaconazole prophylactic regimen. Nevertheless, posaconazole treatment-related severe toxicity, such as hepatotoxicity or cardiotoxicity, occurs very rarely, i.e. <1% [2]. Frequent adverse effects include gastrointestinal disorders, hypokalemia and pyrexia.

Discussion
The main purpose of the implementation of posaconazole TDM into everyday practice is to improve the safety and...
efficacy of posaconazole therapy in pediatric patients in a way that will enable the achievement of optimal prophylaxis efficacy and minimize any possible side effects.

To perform TDM of posaconazole in clinical practice, accurate, validated analytical methods have to be available. Up to now, a dozen methods for the estimation of posaconazole in biological samples have been published. High-performance liquid chromatography with UV [5–8] or FLD [9–11] detection and liquid chromatography-tandem mass spectrometry [12–16] remain the most advantageous in terms of therapeutic monitoring of drugs, because they enable reliable results to be obtained in a relatively short time.

Liquid chromatography with mass spectrometry and tandem mass spectrometry are preferable in sensitivity and specificity to ultraviolet or fluorescence detections. However, such instruments are expensive to purchase and are not affordable in many laboratories. The assay costs often exceed those of the other techniques, which are based on fluorescence (FLD) or ultraviolet (UV) detection. An elaborated procedure involving FLD detection is likely to be a more suitable alternative to routine TDM measurements of posaconazole.

Another point to consider is the sample pretreatment procedure. It is very important to simplify the analytical procedure so that it can be successfully used in therapeutic drug monitoring. Previously published HPLC-UV and FLD methods of posaconazole level measurement still use liquid-liquid extraction (LLE) [6–8, 11] or solid-phase extraction (SPE) [17] to separate the drug from the biological matrix. This is expensive and time-consuming.

Our method is much faster and more easily performed. It is based on one step plasma protein precipitation which reduces the potential errors resulting from changes in extraction efficiency. An extremely important facet of TDM practice is the aliquot of the matrix that is required for analysis, especially in pediatric patients. When compared to previously published HPLC-UV [6–8] or HPLC-FLD [9–11] methods in which the sample volume ranges from 100 to 500 μL, the current method allows the determination of posaconazole in plasma with a smaller serum sample (50 μL) and a smaller injection volume (2 μL). Finally, the total chromatographic run time of the method used is less than 7 min, which is very important in TDM practice when results must be obtained as quickly as possible.

There are some limitations to our study. This was a single-center retrospective study with a small number of patients. The correlation between dosage, the plasma concentration of the drug, and the outcome of treatment was not assessed. No dose adjustment or repeat TDM measurements were performed.

We still have insufficient knowledge on which to build final conclusions, but undoubtedly clinical trials on TDM of posaconazole should be developed. It seems to be especially useful and important to secure reasonable treatment with drugs of unpredictable pharmacokinetics such as posaconazole. Despite the implementation of the drug according to the international dosage recommendations, we failed to obtain the desired plasma concentration in a significant proportion of children.

One possible conclusion after our trial could be that we are unable to assess which factors really influence posaconazole serum concentration. Hence, we will not be able to avoid or modify them. Due to that, therapeutic drug monitoring applied in routine practice should be implemented in Poland.

ECIL-4 and ECIL-8, the Polish Society of Pediatric Oncology and Hematology guidelines on antifungal prophylaxis, clearly recommend the use of TDM in children below a weight of 40 kg [1, 18, 19].

We will aim to assess an extended group of patients with the future roll-out of our research.

Authors’ contributions

Conflict of interest
None.

Financial support
The sources of financial support for our research and publication were The National Center for Research and Development’s BRIdge Alfa and Polish Venture Fund, as well as Wroclaw Medical University grant no B/01/11/2020.

Ethics
The work described in this article has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; EU Directive 2010/63/EU for animal experiments; Uniform requirements for manuscripts submitted to biomedical journals.

References


